Compare RYM & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYM | EVAX |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 33.7M |
| IPO Year | 2021 | 2021 |
| Metric | RYM | EVAX |
|---|---|---|
| Price | $21.06 | $3.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.33 |
| AVG Volume (30 Days) | 22.7K | ★ 68.2K |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,303,000.00 | $7,650,000.00 |
| Revenue This Year | N/A | $128.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1338.92 | 132.17 |
| 52 Week Low | $13.22 | $1.20 |
| 52 Week High | $53.65 | $12.15 |
| Indicator | RYM | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 45.47 | 34.64 |
| Support Level | $17.66 | $3.88 |
| Resistance Level | $19.28 | $4.85 |
| Average True Range (ATR) | 1.48 | 0.36 |
| MACD | -0.04 | -0.09 |
| Stochastic Oscillator | 42.26 | 8.13 |
Rythm Inc is a USA Based company. The Company's portfolio of brands delivers well-being to millions of Americans every year. The company features some of the recognized and trusted names in the cannabis and hemp industries, including RYTHM, incredibles, Dogwalkers, Beboe, Senorita THC Margaritas, &Shine, Doctor Solomon's and Good Green in thousands of physical locations and online channels. With products rooted in quality, safety, and innovation, the Company is shaping cannabis experiences that enhance daily life.
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.